Journal: British journal of cancer

Article Title: TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.

doi: 10.1038/s41416-023-02295-x

Figure Lengend Snippet: Fig. 1 Differential expression of TPX2 in pancreatic cancer. Immunohistochemical detection of TPX2 expression in exemplary PDAC cases showing (a) high TPX2 expression and (b) low TPX2 expression. 200-fold magnification. Scale bars indicate 50 µm.

Article Snippet: TPX2 expression was detected on 4- μm-thick sections by immunohistochemistry on a Ventana Benchmark Ultra autostainer instrument (Ventana, Tucson, AZ, USA) using an anti-TPX2 polyclonal rabbit antibody (HPA005487, Atlas antibodies, Bromma, Sweden) at a 1:100 dilution for 32min, after incubation with cell conditioning reagent 1 (CC1, Ventana) for 64min.

Techniques: Quantitative Proteomics, Immunohistochemical staining, Expressing

Journal: British journal of cancer

Article Title: TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.

doi: 10.1038/s41416-023-02295-x

Figure Lengend Snippet: Fig. 2 High TPX2 expression is associated with dismal prognosis in 1st-line gemcitabine-treated pancreatic cancer patients. Univariate analyses (Kaplan–Meier curves and log-rank tests) for PFS and OS in the gemcitabine 1st-line chemotherapy subgroup (a, b) as well as in the non-gemcitabine 1st-line chemotherapy subgroup (c, d), according to TPX2 expression. Crossed lines indicate censored cases.

Article Snippet: TPX2 expression was detected on 4- μm-thick sections by immunohistochemistry on a Ventana Benchmark Ultra autostainer instrument (Ventana, Tucson, AZ, USA) using an anti-TPX2 polyclonal rabbit antibody (HPA005487, Atlas antibodies, Bromma, Sweden) at a 1:100 dilution for 32min, after incubation with cell conditioning reagent 1 (CC1, Ventana) for 64min.

Techniques: Expressing

Journal: British journal of cancer

Article Title: TPX2 expression as a negative predictor of gemcitabine efficacy in pancreatic cancer.

doi: 10.1038/s41416-023-02295-x

Figure Lengend Snippet: Fig. 3 High TPX2 expression is associated with dismal prognosis in resected pancreatic cancer patients treated with adjuvant gemcitabine-based chemotherapy. Univariate analyses (Kaplan–Meier curves and log-rank tests) for DFS and OS in the gemcitabine-based adjuvant treatment cohort (a, b) and the non-gemcitabine-based adjuvant treatment cohort (c, d) according to TPX2 expression, as well as in the gemcitabine-based treated (e, f) and the non-gemcitabine-based treated (g, h) validation cohorts. Crossed lines indicate censored cases. Association of TPX2 expression and 14 gene-based gemcitabine-resistance expression signature (i). Correlation of TPX2 expression and the expression of gemcitabine-resistance-associated genes (j).

Article Snippet: TPX2 expression was detected on 4- μm-thick sections by immunohistochemistry on a Ventana Benchmark Ultra autostainer instrument (Ventana, Tucson, AZ, USA) using an anti-TPX2 polyclonal rabbit antibody (HPA005487, Atlas antibodies, Bromma, Sweden) at a 1:100 dilution for 32min, after incubation with cell conditioning reagent 1 (CC1, Ventana) for 64min.

Techniques: Expressing, Adjuvant, Biomarker Discovery

Journal: American Journal of Cancer Research

Article Title: MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2

doi:

Figure Lengend Snippet: TPX2 is a direct target of miR-1294 in glioma cell lines. A. Predicted miR-1294 target sequence in the 3’-UTR of TPX2 mRNA. B. miR-1294 down-regulated the luciferase activity of the wild-type TPX2 3’UTR expression vector but did not reduce the expression of mutant TPX2. C. Expression of TPX2 in the CGGA public database. D. Expression of TPX2 in NBTs (n=5) and glioma specimens divided into LGG (n=8) and HGG (n=8). E. Expression of TPX2 in normal human astrocytes (NHAs) and four glioma cell lines (U87, U251, LN229, A172). F. Expression of TPX2 in U87 and U251 cells transfected with NC, miR-1294 mimic or miR-1294 inhibitor. *P<0.05, **P<0.01.

Article Snippet: After incubation with specific primary antibodies against TPX2 (1:1000, Abnova, China) overnight at 4°C, membranes were further incubated for 1 hour with horseradish peroxidase-conjugated secondary antibodies.

Techniques: Sequencing, Luciferase, Activity Assay, Expressing, Plasmid Preparation, Mutagenesis, Transfection

Journal: American Journal of Cancer Research

Article Title: MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2

doi:

Figure Lengend Snippet: Down-regulation of TPX2 suppresses glioma cell proliferation, migration, and invasion and enhances chemosensitivity to temozolomide in vitro. A. qRT-PCR analysis of TPX2 expression in U87 and U251 cells transfected with NC or si-TPX2. B, C. The CCK-8 assay for U87 and U251 cells transfected with NC or si-TPX2. D. The migration assay for U87 and U251 cells transfected with NC or si-TPX2. E. The Transwell for U87 and U251 cells transfected with NC or si-TPX2. F, G. Cell viability was examined for U87 and U251 cells transfected with NC or si-TPX2 following TMZ treatments at various doses. H, I. Cell viability was examined every 24 hours in U87 and U251 cells transfected with NC or si-TPX2 following TMZ treatments at the indicated concentrations. *P<0.05, **P<0.01.

Article Snippet: After incubation with specific primary antibodies against TPX2 (1:1000, Abnova, China) overnight at 4°C, membranes were further incubated for 1 hour with horseradish peroxidase-conjugated secondary antibodies.

Techniques: Migration, In Vitro, Quantitative RT-PCR, Expressing, Transfection, CCK-8 Assay

Journal: American Journal of Cancer Research

Article Title: MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2

doi:

Figure Lengend Snippet: TPX2 overexpression reverses the suppressive effects of miR-1294 on glioma cells in vitro. A. qRT-PCR analysis of TPX2 expression in U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2. B, C. The CCK-8 assay for U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2. D. The migration assay for U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2. E. The Transwell assay for U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2. F, G. Cell viability was examined for U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2 following TMZ treatments at various doses. H, I. Cell viability was examined every 24 hours for U87 and U251 cells transfected with NC, miR-1294 or miR-1294 together with TPX2 following TMZ treatments at the indicated concentrations. *P<0.05, **P<0.01.

Article Snippet: After incubation with specific primary antibodies against TPX2 (1:1000, Abnova, China) overnight at 4°C, membranes were further incubated for 1 hour with horseradish peroxidase-conjugated secondary antibodies.

Techniques: Over Expression, In Vitro, Quantitative RT-PCR, Expressing, Transfection, CCK-8 Assay, Migration, Transwell Assay

Journal: American Journal of Cancer Research

Article Title: MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of glioma to temozolomide via the direct targeting of TPX2

doi:

Figure Lengend Snippet: miR-1294 inhibits glioma growth in vivo. A. Tumor formation was assessed in nude mice, and the tumors of U87 xenografts were excised. B. The volume of excised tumors according to the formula: V (mm3)=0.5 * a* b2 (a represents the longest axis and b the shortest axis). C. The weight of excised tumors. D, E. Expression of TPX2 in tumor tissue. *P<0.05, **P<0.01.

Article Snippet: After incubation with specific primary antibodies against TPX2 (1:1000, Abnova, China) overnight at 4°C, membranes were further incubated for 1 hour with horseradish peroxidase-conjugated secondary antibodies.

Techniques: In Vivo, Expressing